NEX Health Intelligence
Category: AI in Healthcare
AI-powered infection intelligence platform that helps hospitals detect, predict and prevent healthcare-associated infections before they spread. NEX Health Intelligence was founded in 2022. The company is led by Dr Ashleigh Myall. Based in London, United Kingdom. Team size: 2-10. Total funding raised: $1.5M. Latest round: Pre-Seed. Key investors include Brighteye Ventures (lead); Adeline Arts & Science; AFI Ventures (Ventech impact fund); Momentous Ventures; Conception X Angel Syndicate.
- Founded
- 2022
- Headquarters
- London, United Kingdom
- Team size
- 2-10
- Total funding
- $1.5M
Value proposition
NEX's AI platform uses network-based machine learning on hospital contact data to predict where drug-resistant infections will spread days in advance, enabling proactive—not reactive—infection prevention. Clinical evidence published in The Lancet Digital Health (2023) shows hospital-onset infections can be anticipated days before clinical detection.
Products and solutions
NEX Infection Intelligence Platform — combining Risk Intelligence (AI-powered risk scoring for patients/wards), Outbreak Intelligence (detect, investigate and contain outbreaks), and Surveillance Intelligence (streamlined infection surveillance automation) in one clinical-grade system.
Unique value
Predictive infection intelligence that surfaces emerging transmission risks days before standard surveillance detects them, using dynamic patient-contact networks built from existing hospital bed records. Proven clinical impact: up to 68% reduction in active surveillance testing required, 44% increase in screening compliance, 87% reduction in case review time.
Target customer
Hospital Infection Prevention & Control (IPC) teams, NHS Trusts, military hospitals, and international healthcare systems
Industries served
Healthcare; Hospital Infection Control; Antimicrobial Resistance (AMR) Prevention; Public Health
Technology advantage
Proprietary network-based ML models combining dynamic patient-contact networks (built from hospital bed records) with clinical data to predict transmission risk. Published in The Lancet Digital Health demonstrating ability to predict infections days in advance. Clinical-grade: GDPR compliant, Cyber Essentials Plus certified, NHS DTAC/DSPT and DCB0129 Clinical Safety certified. Imperial College London spinout with academic validation from the Fleming Initiative and Centre for Mathematics for Precision Healthcare.
How they differentiate
Unlike traditional infection surveillance tools that are retrospective (counting/reporting past infections), NEX is predictive — using AI and real-time contact-network analysis to forecast where transmissible infections will spread next, days before clinical presentation. Backed by peer-reviewed evidence in The Lancet Digital Health (2023) and validated across hundreds of thousands of patient records. Delivers proactively actionable risk intelligence rather than passive dashboards.
Main competitors
VigiLanz Corporation (US, AI-driven clinical surveillance); Baxter/ICNet International (UK/US, infection surveillance software); RL Datix Ltd (UK, patient safety/risk management); BioVigil (US, hand hygiene compliance)
Key partnerships
NHS organisations (evaluation across two London NHS Trusts; deployment in North West England); Phramongkutklao Hospital (Royal Thai Army military hospital, Thailand); one of Malaysia's largest public hospitals; Imperial College London (academic/research partnership); MedTech SuperConnector; Alan Turing Institute
Notable customers
Two London NHS Trusts (evaluation projects); NHS North West England (deployment); Phramongkutklao Hospital, Thailand (military hospital); One of Malaysia's largest public hospitals; Platform supported infection safety across 40,000+ patient admissions internationally
Major milestones
2023: Landmark study published in The Lancet Digital Health demonstrating predictive infection modelling; 2025: Wins Innovate UK Transformative Technology Grant; Dec 2025: Latest product release drives 114% increase in infection control compliance; May 2026: Raises €1M pre-seed led by Brighteye Ventures; Platform deployed across 40,000+ patient admissions internationally
Growth metrics
Up to 68% reduction in active surveillance testing required; 44% increase in screening compliance; 87% reduction in case review time; 114% increase in infection control compliance rates post-product release; 40,000+ patient admissions covered
Market positioning
Early-stage UK medtech startup with strong academic pedigree (Imperial College London spinout), serving NHS Trusts and expanding internationally into Southeast Asia. Positioned as a predictive, AI-native alternative to legacy retrospective infection surveillance systems.
Geographic focus
UK (NHS), Southeast Asia (Thailand, Malaysia), with plans for broader international expansion
Patents and IP
Landmark study published in The Lancet Digital Health (2023) demonstrating predictive infection modelling; underlying research developed at Imperial College London Departments of Mathematics and Infectious Diseases
About Dr Ashleigh Myall
PhD in Mathematics at Imperial College London; worked on NHS COVID-19 response (bed/ventilator demand forecasting); biodefense and infection detection background; researcher at the Alan Turing Institute
Official website: https://www.nex-intelligence.org/